Slide 1: Results Jan-Jun 2025
Results Jan-Jun 2025 Simon Østergaard President/CEO EVOLVING MICROSCOPY | ELEVATING HEALTHCARE 1
Slide 2: The Quarter in Brief
2 THE QUARTER IN BRIEF Highlights • Robust Result and Mixed Regional Performance Organic sales • The APAC region delivered strong growth growth • Americas and EMEA, quarterly variations resulted in a moderate organic growth Progress on strategic direction • Good progress in advancing our strategic p
Slide 3: Financial Development
3 FINANCIAL DEVELOPMENT MSEK Q2 2025 Q2 2024 YTD 2025 YTD 2024 FY 2024 Net sales 191 188 386 358 723 Organic growth 7.6% 9.9% 11% 16% 7% Gross margin 68% 66% 69% 66% 67% Operating expenses/ sales 41% 40% 41% 42% 43% EBITDA 60 60 126 109 219 EBITDA margin 31% 32% 33% 30% 30% R&D spend/ sales 22% 19%
Slide 4: Regional Highlights
4 REGIONAL HIGHLIGHTS AMERICAS EMEA APAC -2% 3% -4% 19% 23% 8% (Q2 2025/24) (YTD 2025/24) (Q2 2025/24) (YTD 2025/24) (Q2 2025/24) (YTD 2025/24) • Sales amounted to SEK 66 m (67) • Sales amounted to SEK 80 m (83) • Sales increased to SEK 46 m (37) • Organic growth 5%, currency effect -7% • Organic gr
Slide 5: Sales per Product Group
5 SALES PER PRODUCT GROUP INSTRUMENTS REAGENTS SOFTWARE & OTHER -2% 11% 7% 6% 6% 3% (Q2 2025/24) (YTD 2025/24) (Q2 2025/24) (YTD 2025/24) (Q2 2025/24) (YTD 2025/24) • Sales amounted to SEK 106 m (107) in the quarter • Sales increased to SEK 38 m (35) in the quarter • Sales increased to SEK 48 m (45)
Slide 6: Key Takeaways
6 FINANCIAL KEY TAKEAWAYS AMBITION • Q2 showed Robust Result and Mixed Regional Performance CAGR of EBITDA margin ~15% >30% • All regions contributing to organic growth • High level of activity across our R&D portfolio • Strategic partnership has gained considerable momentum • The Power of Focus str
Slide 7: Financial Calendar
7 FINANCIAL CALENDAR November 6, 2025 Interim Report January-September February 5, 2026 Year-end Bulletin 2025